Hyoscine Butylbromide Injection

Product Details
Customization: Available
Type: Biological Products
Pharmaceutical Technology: Chemical Synthesis
Still deciding? Get samples of US$ 0/Piece
Request Sample
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Management System Certification
ISO 9001, GMP, ISO 13485, FSC
Import & Export Mode
Have Own Export License
  • Hyoscine Butylbromide Injection
  • Hyoscine Butylbromide Injection
  • Hyoscine Butylbromide Injection
  • Hyoscine Butylbromide Injection
Find Similar Products

Basic Info.

Model NO.
AMC14014
Shelf Life
3 Years
OEM
Available
Registration Dossiers
Available
Transport Package
100′s/Box
Specification
GMP
Trademark
Medipharm, OEM
Origin
China
HS Code
30042090
Production Capacity
50000 Boxes Per Month

Product Description

Hyoscine Butylbromide Injection
 
Description
 It is a sterile solution. Hyoscine Butylbromide in water for injections.Each ampoule
contains Hyoscine Butylbromide 20mg or each ampoule contains Hyoscine Butylbromide
lOmg.
 
INDICATIONS:
Hyoscine is a tertiary amine antimuscarinic agent with central and peripheral actions.lt
is a more powerful suppressant of salivation than atropine,and usually slows rather than
increases heart rate,especially in low doses.Its central action differs from that of atropine in
that it depresses the cerebral cortex and produces drowsiness and amnesia.Hyoscine
butylbromide is quaternary ammonium derivatives.
Hyoscine is effective in the prevention and control of motion sickness and has also
been given as an antiemetic in the prophylactic treatment of other forms of nausea.Hyoscine
is also given to prevent motion sickness via a transdermal delivery system which is placed
behind the ear and supplies 500 <xg over 3 days.
 
ADVERSE EFFECTS AND PRECAUTIONS:
In contrast to atropine,hyoscine produces central depression at therapeutic doses and
symptoms include drowsiness and fatigue.Toxic doses of hyoscine produce stimulation of
the CMS in a similar manner to atropine.However,hyoscine does not stimulate the medullary
centres and therefore does not produce the increases in respiration rate or blood pressure
seen with atropine.Hyoscine may produce CNS stimulation rather than depression at
therapeutic doses if used in the presence of pain without opioid analgesics; symptoms include
excitement,restlessness,hallucinations,or delirium.
Hyoscine should not be used concurrently wih CNS depressants.Caution has been advised
in elderly patients and in patients with impaired metabolic,liver,or kidney function,as adverse
CNS effects have been stated to be more likely in these patients.There have been rare reports
of an increase in frequency of seizures in epileptic paticnts.The quaternary derivatives, such
as the butylbromide do not readily cross the blood-brain barrier,so central effects are rare.
 
ADMINISTRATION:
Hyoscine has been given as its quaternary ammonium derivatives in conditions
associated with visceral spasm,in usual doses of 20 mg of the butylbromide intramuscularly
or intravenously,repeated after 30 minutes if necessary.The use of antimuscarinics in the
relief of visceral spasms of the gastrointestinal tract is discussed on;they may also relieve
painful spasms of the biliary and genitourinary systems,although analgesics are normally
used.
 
AVAILABILITY:
Ampoule of Iml-box of 100 ampoules.
STORAGE:
Preserve in well closed container,prolected from light and stored in a
cool place.
Hyoscine Butylbromide Injection
Hyoscine Butylbromide Injection
Hyoscine Butylbromide Injection
Hyoscine Butylbromide Injection
Hyoscine Butylbromide Injection
Hyoscine Butylbromide Injection




 
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier